Try our Advanced Search for more refined results

In re Solodyn (Minocycline Hydrochloride) Antitrust Litigation

Track this case

Case overview

Case Number:

1:14-md-02503

Court:

Massachusetts

Nature of Suit:

Anti-Trust

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

Denise J. Casper

Firms

Companies

Sectors & Industries:

  1. March 01, 2018

    Valeant To Shell Out $58M To End Solodyn Pay-For-Delay MDL

    Valeant Pharmaceuticals International Inc. on Wednesday said it will pay more than $58 million to end pay-for-delay litigation in Massachusetts federal court alleging subsidiary Medicis Pharmaceutical Corp. illegally kept a generic for the acne medication Solodyn off the market.

  2. February 13, 2018

    1st Circ. Denies Bid To Stall Solodyn Pay-For-Delay Trial

    The First Circuit on Monday denied an attempt by Valeant Pharmaceuticals subsidiary Medicis Pharmaceutical Corp. to stall a March trial slated to decide whether the company paid generic-drug makers to stay out of the market for acne medication Solodyn.

  3. January 25, 2018

    Medicis Falls Short In Bid To Escape Pay-For-Delay Suit

    A Massachusetts federal judge on Thursday shot down acne-drug maker Medicis' attempt to escape allegations it participated in a pay-for-delay scheme to keep competing generics out of the market, saying a jury must decide numerous disputes of fact in the case.

  4. January 02, 2018

    Lupin, Sandoz Settle With Retailers In Solodyn Suit

    Generic-drug makers Lupin Ltd. and Sandoz Inc. settled with Walgreen Co., CVS Pharmacy Inc., Rite Aid Corp. and other retailers over allegations in Massachusetts federal court that the manufacturers had accepted payments from Medicis Pharmaceutical Corp. to stay out of the market for acne medication Solodyn.

  5. December 11, 2017

    Retailers Defend Solodyn MDL Claims Against Medicis

    Walgreen Co., CVS Pharmacy Inc., Rite Aid Corp. and other retailers alleging Medicis Pharmaceutical Corp. paid generic-drug makers to stay out of the market for acne medication Solodyn urged a Massachusetts federal court Monday to reject Medicis' efforts to nix some of their claims.

  6. November 22, 2017

    Medicis, Solodyn Buyers Duel For Quick Wins In Antitrust MDL

    Medicis Pharmaceutical Corp. and two classes of Solodyn buyers have each asked a Massachusetts federal court for quick wins to end the buyers' pay-for-delay suit accusing Medicis of paying generic-drug makers to stay off the market for the acne medication, with the parties fighting over how much competition exists.

  7. October 16, 2017

    End-Payors, Direct Purchasers Get Cert. In Solodyn MDL

    End-payor and direct purchasers' bids for class certification were granted in Massachusetts federal court Monday in the pay-for-delay litigation against drugmakers Medicis Pharmaceutical Corp. and Impax Laboratories Inc. over the generic version of Medicis' acne medication Solodyn.

  8. April 04, 2017

    Sandoz, Lupin To Pay Combined $6.7M In Pay-For-Delay MDL

    Sandoz Inc. and Lupin Ltd. have agreed to pay a combined $6.7 million to exit multidistrict litigation accusing them of striking a deal with a Valeant Pharmaceuticals Corp. unit to delay launching their generic versions of the acne medication Solodyn, according to a pair of proposed deals Tuesday.

  9. August 14, 2015

    Monopoly Claims Nixed In Solodyn Pay-For-Delay Suit

    A Massachusetts federal judge on Friday pared down multidistrict litigation accusing Medicis Pharmaceutical Corp. of paying off several generic drugmakers to delay launching their own versions of acne medication Solodyn, but allowed the core pay-for-delay allegations to go forward.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!